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Abstract—Chronic total occlusions (CTOs) represent the
‘‘last frontier’’ of percutaneous interventions. The main
technical challenges lies in crossing the guidewire into the
distal true lumen, which is primarily due to three problems:
device buckling during initial puncture, inadequate visual-
ization, and the inability to actively navigate through the
CTO. To improve the success rate and to identify future
research pathways, this study systematically reviews the
state-of-the-art of all existing and invented devices for
crossing occlusions. The literature search was executed in
the databases of Scopus and Espacenet using medical and
instrument-related keyword combinations. The search
yielded over 840 patents and 69 articles. After scanning for
relevancy, 45 patents and 16 articles were included. The
identified crossing devices were subdivided based on the
determinant for the crossing path through the occlusion,
which is either the device (straight and angled crossing), the
environment (least resistance, tissue selective, centerline, and
subintimal crossing) or the user (directly steered and sensor
enhanced crossing). It was found that each crossing path is
characterized by specific advantages and disadvantages. For
a future crossing device, a combination of crossing paths is
suggested were the interventionist is able to exert high forces
on the CTO (as seen in the device approach) and actively
steer through the CTO (user: directly steered crossing) aided
by intravascular imaging (user: sensor enhanced crossing) or
an intrinsically safe device following the centerline or path of
least resistance (environment: centerline crossing or least
resistance crossing) to reach the distal true lumen.
Keywords—Chronic total occlusions (CTO), Crossing, Per-
cutaneous coronary intervention (PCI), State of the art,
Treatment, Recanalization, Review.
INTRODUCTION
It is often stated that chronic total occlusions
(CTOs) represent the ‘‘last frontier’’ of percutaneous
coronary interventions (PCIs).55 This statement is
substantiated by the fact that PCIs in CTOs have
considerably lower procedural success rates, in
between 55 and 90%, than those achieved in non-oc-
cluded or acutely occluded coronary vessels (>95%),
with the higher success rates in the hands of a few
dedicated expert operators.19,51,55 The main contribu-
tor to the lower success rates seen in PCIs of CTOs is
the technically challenging procedure, which requires a
long learning curve and high technical skill from the
interventional cardiologists. Even though recent ad-
vances in guidewire, catheter, and crossing device
technologies have steadily increased the technical and
procedural success rates of PCIs in CTOs over the last
5 years, CTOs still remain the lesion subtype in which
PCI is most likely to fail.55 Therefore, improvement is
still required to reach a widespread 95% success rate of
PCIs in CTOs, for even the less experienced operators.
The main technical challenge during PCIs in CTOs,
accounting for approximately 80% of procedural fail-
ure, lies in guidewire crossing into the true lumen of the
distal vessel primarily due to three problems.55 Firstly,
currently available equipment, including guidewires and
crossing devices, are often unable to physically cross the
tough fibrous cap of the CTO. The small diameter
(<0.4 mm) andflexibility of the guidewire (and crossing
devices alike) result in limited bending stiffness.
Attempting to penetrate the tough proximal cap,
therefore, often causes buckling. Since acute lesions are
softer and have no fibrous cap, buckling is usually not
observed, explaining the higher success rate. Secondly,
even if the initial puncture is successful, crossing the
CTO remains challenging due to inadequate 3D visual-
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ization during the crossing procedure. This inadequate
visualization complicates navigating and can, therefore,
cause blood vessel wall trauma, false lumen creation,
and even discontinuation of the procedure due to
uncertainty about the position of the guidewire.51,55
Thirdly, the inability to actively navigate across the
CTO to, for example, compensate for guidewire deflec-
tion by heavily calcified regions or cross highly tortuous
vessels, complicates reaching the distal true lumen.
Based on these three main challenges in PCIs of
CTOs an international panel of 47 physicians has
drafted three main requirements a CTO crossing device
must meet to increase the success rate.54 First of all, the
crossing device should be able to move forward even
through resistant fibrotic and calcified tissue, either
through mechanical means or by using an energy
source. Secondly, the crossing device should be able to
detect and ensure correct intraluminal passage. Fi-
nally, the crossing device should be able to precisely
steer through the CTO.
Despite advances in equipment, with crossing de-
vices incorporating at least one of the abovementioned
functionalities, CTO recanalization may still be
unsuccessful in approximately 25% of cases.55 As of
today, a device incorporating all three of the proposed
functionalities is still a work-in-progress. Therefore, it
is a necessity to fundamentally explore new ways to
safely and effectively cross CTOs and incorporate the
three main functionalities that could in future increase
the success rate in PCIs of CTOs.
A review of the state-of-the-art in crossing devices
could potentially give insight into a future crossing
device that incorporates all these functionalities. Even
though some reviews exists that describe the current
state-of-the-art in crossing devices specifically designed
for CTOs, these reviews are incomplete as they mainly
focus on providing an overview of currently applied
devices; excluding the patented literature.30,55,63 This
study explores the entire field, including the patented
literature, and systematically reviews the state-of-the-
art of all existing and invented crossing devices and
methods for crossing total occlusions, including acute
occlusions (which are usually softer (thrombotic) than
CTOs, which are mainly characterized by heavy cal-
cification), used in clinical practice and designs de-
scribed in the patented literature. The study ends in a
discussion in which we identify future research path-
ways that could lead to a fundamental improvement in
the field.
LITERATURE SEARCH METHOD
A literature search was executed in the database of
Scopus and Espacenet and was limited to the English
or Dutch language from the 1950s to the present. The
search was broadened to include all kinds of occlu-
sions, including acute and semi-occluded lesions, to get
a complete overview of all the devices available for
crossing obstructions in the vascular system.
The search terms in the Scopus search engine were
subdivided into four categories: (1) occlusion, (2)
treatment, (3) medical area, and (4) instrument type. In
the occlusion category, the search terms: occlu*, ob-
struct*, plaqu*, thromb*, *clot*, obstacle*, and barrier*
were used. The treatment category included: *canal*,
remov*, resect*, dissect*, and cut*. In the area cate-
gory, the following terms were used: vasc*, cardio*,
arter*, vessel*, vein*, and cappilar*, and in the instru-
mental category: device*, instrument*, prototype*,
guidewire*, catheter*, and apparatus*. The categories
were connected with the ‘‘AND’’ operator; the search
terms either with ‘‘AND’’ or ‘‘OR’’. The ‘‘NOT’’
operator was added to filter out non-relevant articles.
The final literature search in Scopus led to 69 hits.
Of these hits, first the titles were scanned for relevancy,
after which the abstract was read. If it was concluded
that the article fitted the scope of this review as dis-
cussed in the previous section, it was included in this
review. This led to a total of 16 articles being included
in this review.
Subsequently, the Espacenet database was searched
for patents relating to crossing devices for occlusions
using the following keywords in the title and in the title
and abstract, respectively: (occlu* OR obstruct* OR
plaqu* OR thromb* OR clot*), and ((vasc* OR vessel*)
AND (canal* OR remov* OR resect*)). This led to 845
potentially relevant patens. By first reading the title of
the patents, followed by the summary of the invention,
a total of 42 were selected.
STATE OF THE ART DEVICES
It was found that there are multiple ways or meth-
ods to cross an occlusion and reach the true lumen at
the distal (or proximal) end of the blood vessel. Which
path is followed depends on the chosen crossing device.
Three main approaches can be distinguished: the De-
vice, Environment, and User approach (see Fig. 1). Per
approach, the associated devices will be discussed and
the intended use, i.e., for acute occlusions or CTOs,
and current status, i.e., abandoned, in use, or proposed
(amongst others) will be indicated.
Device
In the Device approach, the crossing device itself is
the most determining factor for the crossing path. The
occlusion is crossed in a straight or angled manner,
SAKES et al.104
independent of the properties and geometry of the
occlusion and blood vessel, as well as the input from
the user, called Straight Crossing or Angled Crossing,
respectively.
Straight Crossing
Developed devices that cross the CTO in a straight
line use a fluidic (fluid jets) or gaseous medium (lasers)
(Fig. 2). The initial orientation of the tip of these de-
vices determines the crossing direction. It is, therefore,
imperative that the tip of the device is perpendicular to
the CTO cap and, as best as can be achieved, collinear
to the lumen. The crossing speed is controlled by the
input power of the laser or fluid jet.
Fluid Jets (Abandoned, Originally in Use for Acute
Occlusions) In hydrodynamic thrombectomy, a
high-velocity fluid jet is used to fragment and remove
occlusive material from the blood vessel wall. For this
purpose, high-velocity fluid jets use a fine stream of
saline at high pressures (typically between 15 and
20 kg/cm2). Currently, fluid jets used for crossing
purposes are abandoned due to safety concerns (note
that some still exist for treating purposes). However,
Nguyen et al.22 and Delaney et al.11 propose axially
directed fluid jets for crossing acute occlusions (Fig. 2).
Lasers (in Use for Peripheral and Coronary
CTOs) Medical lasers use a high-energy beam of
light to resect or dissolve different tissue types for
crossing or debulking purposes. Absorption of the
laser energy within the targeted biological tissues
creates photochemical and photomechanical reactions
that result in conversion of the plaque material in
vapor and the development of acoustic shock waves
that are able to fragment tissue. Lasers, such as over-
the wire and rapid-exchange excimer laser catheters,
are currently in use for CTO crossing in atherectomy.
These laser catheters contain a flexible fiber-optic cable
made out of as many as 240 high-purity silica fibers
arranged around a guidewire lumen, with the distal
tip polished and rounded. Examples of laser
crossing systems are the CVX-300 Excimer Laser
(Spectrametrics Inc., Colorado Springs, CO) and the
TURBO elite laser ablation catheter (FDA approved
October, 2006).63 Furthermore, in3,18,40,44 different
lasers are proposed for crossing acute occlusions and
CTOs (see Fig. 2 for the laser devices proposed by
Roth et al.44 and Fischer et al.18).
Unfortunately, heat accumulation is often an issue in
lasers, warranting careful advancement through the
CTO, slower than 1 mm/s, to increase absorption of the
plaque and prevent absorption by the blood vessel
wall.63 To minimize this problem, Pallarito et al.40 and
Roth et al.44 suggest using focusing devices (lenses) to
narrow the laser beam (see Fig. 2 for the device
proposed by Roth et al.). Despite the drawback of
heat accumulation, a major advantage of lasers is that
buckling is no issue as there are nomechanical forces on
the device tip.
FIGURE 1. CTO crossing methods—overview. Per crossing method the associated references are illustrated in between brackets.
Color indications: Red 5 blood vessel. Yellow 5 plaque material. White 5 calcified regions. Green 5 sensor.
FIGURE 2. Device: straight crossing. Color indications:
Red 5 blood vessel wall. Yellow 5 plaque material. Light
blue 5 balloon. Blue 5 liquid. Purple 5 laser.
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Angled Crossing
Many of the current and proposed crossing devices
have a rigid tip (L> 2 mm). Since rigid tips do not
allow for bending or compression, the tips of these
devices cannot adjust to the 3D shape and direction of
the CTO. In the flexible device shaft behind the rigid
tip, however, bending is possible, which allows for
some adjustment to bends in the vascular system when
high radial resistance is encountered. The route
through the CTO is, therefore, not smooth, but con-
tains multiple acute angles, which from here on out will
be referred to as Angled Crossing.
Hinged Crossing Device (in Use for Peripheral and
Coronary CTOs) Frontrunner XP (Ø0.76–1 mm, 2.8
F distal tip, Cordis Corporation, Miami, FL)55 is an
FDA-approved crossing device specifically designed
for crossing heavily calcified CTOs.9 Frontrunner XP
uses a hinged bilateral distal tip assembly to cross and
subsequently treat the occlusion via the principle of
blunt microdissection (see Fig. 3 for a similar device is
described by Maschke et al.33).33,55 According to
Mossop et al.,63 procedural success of up to 91% can
be achieved in peripheral CTOs.
Axially Rotating Drills (in Use for Peripheral CTOs
and Acute Occlusions) In atherectomy, axially
rotating drills are used to resect and remove plaque
from the blood vessel wall. There are three main types
of axially rotating drill atherectomy devices: orbital,
rotational, and directional. The three main drill types
mainly differ in drill bit design.
Current FDA-approved rotating drill atherectomy
devices are the Clot Buster Amplatz Thrombectomy
Device catheter (Ø2.7 mm, L = 50 and 120 cm; ATD,
Microvena, White Bear Lake, MN; in use for peripheral
acute occlusions) (Fig. 3)12 and the Wildcat catheter
(Avinger, Redwood City, CA; in use for peripheral
CTOs).42 Success rates of 83 and 89% are reported in
peripheral total occlusions with ATD and Wildcat
catheter, respectively.42 ATD is actuated by compressed
air, rotatinga shieldedhelical cutter at 150,000 rpm.12This
rotation causes negative pressure in close proximity to the
cutter, which sucks the occlusivematerial towards the drill
to macerate it. The Wildcat catheter, in comparison, is
rotatedbyhandanddrivenbyaflexible drive shaft.The tip
can be altered while inside the body from a passive into an
active (more aggressive) configuration. Furthermore,
in5,23,37 multiple additional rotating drill atherectomy
devices are proposed for crossing acute (thrombotic)
occlusions and CTOs (see Fig. 3 for the drill designs
proposed by Bashiri et al.5 and Nash et al.37).
Drive Belt Mechanism (Proposed for Acute
Occlusions) Thompson et al.57 propose a drive belt
mechanism equipped with abrasive devices that shave
off and remove small amounts of clot material at a
time (Fig. 3).
Environment
In the Environment approach, the direct environment
around the device is the determinant for the crossing
path. The environment around the device consists of the
CTO and the blood vessel (wall). In CTO Guided
Crossing, the difference between biomechanical prop-
erties throughout the CTO is the determining factor for
the crossing path. In Blood Vessel Guided Crossing, the
blood vessel is used as a guide for crossing.
CTO Guided Crossing
Two different CTO guided crossing paths can be
distinguished: Least Resistance Crossing and Tissue
Selective Crossing. In the first approach, less (pressure)
resistant tissue types, such as fat, or micro vessels are
used to cross the occlusion. This method is, amongst
others, used by guidewires; the most common crossing
device used in PCI. In the second approach, specific
tissue types are targeted, such as calcium, fibrin, or fat,
to cross the CTO. Which tissue is targeted depends on
the type of crossing device used.
Least Resistance Crossing
Guidewires (in Use for Coronary CTOs, Peripheral
CTOs, and Acute Occlusions) Guidewires are thin
(Ø0.22–0.40 mm for coronary application54) flexible
wires that are inserted into the vascular system to cross
FIGURE 3. Device: angled crossing. Color indications:
Red 5 blood vessel wall. Yellow 5 plaque material. Light
Blue 5 balloon.
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occlusions (CTOs and acute occlusions) and guide other
endovascular instruments, such as support and balloon
catheters, typically during angioplasty. They usually
consist of an inner core and outer spring-coil or polymer
jacket.51
As of today, guidewires remain the crossing tool of
choice during PCI.Many of the discussed devices can be
used in conjunction with a guidewire, but this is not a
prerequisite. Over the last 5 years, the introduction of
better guidewire designs (with higher tip loads, i.e., load
in grams [g] at which the guidewire start to buckle,
amongst others) has drastically improved the success
rate of PCIs in CTOs.51,55 Dedicated CTO guidewire
designs differ based on core design, the presence or
absence of a polymer cover, tip design, and the type of
coating (Table 1).51
Cores of contemporary dedicated CTO guidewires
differ based on the diameter (with higher tip loads with
increasing core diameter), the material used; stainless
steel or nitinol, and the presence of core tapering. CTO
guidewires with stainless steel cores, such as Whisper
(Abbott Vascular, Abbott Park, IL, USA) and Pilot
((Abbott Vascular, Abbott Park, IL, USA), provide
excellent support and tracking abilities (i.e., the ability
of the guidewire body to follow the tip around bends).
However, they are less flexible and more susceptible to
buckling (i.e., have lower tip loads) than guidewires with
nitinol cores, such as Crosswire (Terumo, Tokyo,
Japan).4,15
Another important factor influencing the tip load,
support, and trackability of a guidewire is core tapering.
Gradualor long tapers (in, for example,Gaia (Asahi Intecc.
Corp., Nagoya, Japan)) provide less support and lower tip
loads, but show greater trackability than short tapers (in,
for example, Confianza (Asahi Intecc. Corp., Nagoya,
Japan)).Tapered coredesigns are alsoproposedby31,39 (see
Fig. 4 for the design proposed by Lupton et al.31).
Placed over the core is either an outer coil or polymer
cover.15 An outer coil (such as in Persuader (Medtronic,
Minneapolis, MN, USA)) adds flexibility to the distal
part of the guidewire and affects the support, tracking,
and visibility. Instead of outer coils, some guidewires
have a polymer or plastic covering over the tapered wire
core (such as inWhisper (Asahi Intecc. Corp., Nagoya,
Japan)). Polymer covers provide smooth tracking
through torturous blood vessels.
Two different tip designs can be distinguished:15 the
core to tip (C2T) design (in which the core of the
guidewire is fully extended to the tip (such as in
Runthrough NS (Terumo Medical Corp., Tokyo,
Japan))) and the shaping ribbon (SR) design (in which
the core is not fully extended to the tip; instead a small
piece ofmetal bridges the gapbetween the endof the core
and the tip (such as in PT Graphix Intermediate (Boston
Scientific, Natick, MA, USA))). The C2T design results
in amore responsive guidewire, whereas the SR design is
characterized by a more atraumatic flexible tip.
Additionally, enlarged resilient tip portions (including
the Magnum wire (Schneider, Zurich, Switzerland))1,34
(see Fig. 4 for the design proposed by Abele et al.1) are
proposed to increase the tip load.
In order to decrease the sliding friction, low friction
coefficient guidewires containing a hydrophilic (HI),
hydrophobic (HO; polymeric), or hybrid (HY) coating
(e.g., Confianza (Asahi Intecc. Corp., Nagoya, Japan))
are currently available. Hydrophilic coatings attract water
and become gelatinous when wet, reducing friction, while
hydrophobic coatings repelwater, andalso reduce friction,
butnot to the sameextent ashydrophilicwires.51Available
dedicated CTO guidewire types with a hydrophilic
polymeric coating on the tip are (amongst others) Fielder
(Asahi Intecc, Nagoya, Japan) and Conquest Confianza
(Asahi Intecc, Nagoya, Japan).7,19,20 Additionally, two
patents1,24 discuss the use of a hydrophilic coating, and
Fearnot et al.17 suggest aguidewirewithanantithrombotic
coating to decrease friction by dissolving the occlusion in
direct contact with the guidewire.
According to Sianos et al.,51 the dedicated CTO
guidewires should be used in conjunction with a micro
catheter in order to prevent flexion and buckling (by
improving its columnar strength), and as such improve the
chance of a successful crossing procedure. Currently,
several different (micro) guiding catheters, such as Tornus
(Asahi Intecc, Nagoya, Japan), CrossBoss (Boston
Scientific, Natick, MA, USA), and Corsair (Asahi Intecc,
Nagoya, Japan) are available that have proven successful
in increasing the buckling resistance of dedicated
guidewires. Furthermore, Montague et al.36 also
proposes to use an introducer sheath (or micro catheter)
to improve the columnar strength of the guidewire.
Another challenge in PCI of CTOs is the balloon
uncrossable occlusion, in which the guidewire
successfully crosses the occlusion, but neither a
ballooncatheter nor microcatheter can be advanced
through the CTO, seen in about 2% of the failure
cases.51,55 If this is encountered, several strategies can be
applied:51 (1) a second stiff guidewire can be placed
proximal to the CTO (preferably in a side-branch), (2) a
second balloon can be inflated proximal to the CTO
(preferably in a side branch), or (3) the balloon or
microcatheter can be exchanged for a Tornus (Asahi
Intecc, Nagoya, Japan) to enlarge the lumen.
Furthermore, to overcome this problem altogether,
multiple patents describe combined crossing and
treatment tools (see Fig. 4 for the devices proposed by
Samson et al.47 andGerberding et al.21).14,21,24,29,46–48,56
In these designs, a cable-actuated or self-expandable
cage-like structure is described that in collapsed state
functions as a guidewire and in expanded state as a
treatment device, similar to a stent.
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Crack Propagation Crossing (Proposed for Peripheral
CTOs, Coronary CTOs, and Acute Occlusions) In the
crack propagation crossing method, proposed by
Zakai et al.64 (see Fig. 4), an elevated pressure
between the crossing device and occlusion is used to
‘‘crack’’ or fragment the occlusion at its weakest
region. Crack formation and propagation along the
occlusion follows the path of least resistance until the
distal side is reached and the pressure drops.
Tissue Selective Crossing
Spark Erosion (Proposed for Coronary CTOs) In the
spark erosion crossing method proposed by Bom
et al.,6 two electrodes, placed in close proximity to
the occlusion, generate sparks to fragment and cross
occlusions (Fig. 5). In this method, the electric
conductivity of the tissue types determines the
crossing path. As less electrically conductive
materials, such as calcium, are not fragmented,
whereas those that are electrically conductive, such as
collagen and blood, are fragmented, this crossing
method is less suitable for highly calcified CTOs.
Mechanical Vibration (in Use for Peripheral and
Coronary CTOs) In the mechanical vibration
crossing method it is hypothesized that selective
penetration depends on the difference in elasticity
between the different tissue types. Collagen rich
structures, such as the blood vessel wall, are not
damaged by vibrational energy as they are elastic and,
therefore, move out of the way. In contrast, less elastic
atherosclerotic plaque tissue is not able to move out of
the way and is thus fragmented.
Mechanical vibration energy is used in vibrational
angioplasty. A current FDA-approved vibrational
angioplasty device for crossing CTOs is the Crosser
Catheter (originally developed by FlowCardia,
Sunnyvale, CA, currently by BARD Peripheral
vascular Inc., Tempe, AZ, USA) that consists of a
nitinol transmission wire with a blunt tip and a
generator.25,30,65 The Crosser Catheter uses high
frequency (21 kHz) low-amplitude vibration energy
to break through the cap and subsequently the CTO. A
success rate of in between 40 and 75% was reported
with this device in peripheral CTOs.25,30 In another
currently available vibrational angioplasty device
designed by Medical Miracles (UK), a success rate of
in between 75 and 77.4% was reported in coronary
CTOs.55,63 In this device, a conventional coronary
angioplasty guidewire is guided through a catheter and
vibrated using reciprocal and lateral movements with
frequencies between 16 and 100 Hz.55,63 Richter et al.43
propose a similar device for crossing, in which a distal
attachment mechanism couples a guidewire to the
catheter and allows for a vibrating-generating means
to add axial vibrating motion to the guidewire tip (see
Fig. 5).
Cavitation (Proposed for Peripheral CTOs, Coronary
CTOs, and Acute Occlusions) In the cavitation
FIGURE 4. Environment CTO: least resistance crossing.
Color indications: Red 5 blood vessel wall. Yellow 5 plaque
material. Light blue 5 balloon. Blue 5 liquid.
FIGURE 5. Environment CTO: tissue selective crossing.
Color indications: Red 5 blood vessel wall. Yellow 5 plaque
material. Bright Yellow (in upper left schematic illustra-
tion) 5 electrodes. Purple 5 laser. Green 5 antithrombotic
agent.
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crossing method, small cavitation bubbles are used to
fragment specific tissue types. These cavitation bubbles
are formed by rapid blood pressure changes, which
cause the bubbles to implode, creating shockwaves that
are able to fragment tissue. Tissues with high water
content (such as fat) or brittle tissues (such as calcium)
are fragmented, but vessels and nerves, which have
high collagen content, are preserved.
Cavitation—Ultrasonic Dissection In ultrasonic
dissection, cavitation bubbles are created using
longitudinal vibrations generated by an ultrasonic
generator (e.g., a piezoelectric crystal or a magnetic
field). Siegel et al. describes a series of experiments in
peripheral CTOs with an ultrasonic probe system
consisting of a piezoelectric transducer, multiple
titanium wires to transfer the ultrasonic energy to the
tip of the device, and a Ø2.0 mm ball-shaped tip.52
Similar devices are proposed by Wang et al.61 (for
acute occlusions), Nita et al.38 (for all occlusion types),
and Carmeli et al. (for CTOs)8 (see Fig. 5 for the
design proposed by Carmeli et al.8). Siegel et al.52
showed that heavily calcified regions resist
recanalization with the ultrasonic probe, making this
method less suited for crossing older, more calcified,
CTOs. To increase the effectiveness of ultrasonic
dissection in acute occlusions, Evans et al.16 propose
the addition of thrombolysis (see Fig. 5).
Cavitation—Laser Another method to create
cavitation bubbles for tissue fragmentation is a laser,
as proposed by Visuri et al.60 (see Fig. 5). In this
technique, small-pulsed burst of laser light are used to
create cavitation bubbles that are able to fragment
tissues with high water content.
Blood Vessel Guided Crossing
In Blood Vessel Guided Crossing, the blood vessel
wall is used for support during the crossing procedure.
A subdivision is made between crossing devices that
use the blood vessel wall to cross via the centerline of
the blood vessel, called Centerline Crossing, and
crossing devices that cross subintimally, i.e., between
the intima and adventitia of the blood vessel wall, and
use the support of these layers of the blood vessel wall
for crossing, called Subintimal Crossing.
Centerline Crossing
Centerline following can be achieved with expanding
or elastic self-centering mechanisms. In these devices
the blood vessel wall is used for supporting and cen-
tering the crossing device. Not only does this support
prevent blood vessel wall dissection or puncture, it also
increases the buckling resistance of the tip of the
guidewire or crossing device by increasing the effective
diameter of the device. It must be noted, however, that
if the crossing device is not translated exactly forward
with the self-centering mechanism, true centerline fol-
lowing will be difficult in tortuous and longer occlu-
sions.
Balloons (Undergoing Clinical Trials and Proposed for
Peripheral CTOs) The centerline crossing
ENABLER-P Balloon Catheter System (EndoCross
Ltd., Yokneam, Israel), described by Buchbinder, is
currently undergoing clinical trials for crossing
peripheral CTOs.63 ENABLER-P uses a specially
designed support balloon that allows the balloon to
elongate upon additional cyclical inflation, and as such
moves a standard guidewire 3 mm forward without
exceeding its inherent diameter. Multiple inflation/
deflation cycles advances the guidewire forward
through the occlusion. With this device, successful
guidewire crossing was achieved in 86.4% of the
cases.63 Furthermore, Roucher et al.45 and Kim
et al.26 propose to use a balloon in combination with
a central crossing tool for centerline crossing of CTOs
(see Fig. 6).
Expanding Shape Memory Materials (SMA)
(Proposed for Acute Occlusions) Currently no
clinically tool is available or undergoing clinical trails
using expanding SMMs, such as shape memory alloys
(SMAs) and shape memory polymers (SMPs).
However, Vardi et al.,59 Eckhouse et al.,13 and Stinis
et al.53 propose a mechanism using (self-) expanding
SMAs, such as nitinol, to mimic the shape of the blood
vessel wall in combination with a central crossing
device (see Fig. 6 for the designs proposed by
Eckhouse et al.13 and Stinis et al.53). Furthermore, in
the designs of Eckhouse et al.13 and Stinis et al.53 the
self-centering mechanism is translated forward with
FIGURE 6. Environment blood vessel: centerline crossing.
Color indications: Red 5 blood vessel wall. Yellow 5 plaque
material. Light blue 5 balloon.
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the crossing device, in principle allowing for true
centerline following (Fig. 6).
Subintimal Crossing
Due to the stiff proximal and distal cap of the CTO, the
guidewire or crossing device will sometimes penetrate
the intima and cross the CTO subintimally (between the
intima and adventitia of the blood vessel wall). During
subintimal crossing, the support of both the intima and
adventitia keeps the crossing device collinear to the
direction of the blood vessel wall and prevents perfo-
ration. This support, however, makes reentry into the
true lumen difficult and is often time consuming.30
Multiple specialized subintimal crossing and reentry
devices are currently in use and being developed to
improve reentry to the true lumen, including the Out-
back Catheter (Cordis Corporation, Bridgewater, NJ),
the Pioneer Catheter (Medtronic Inc., Santa Rosa,
CA), and the Stingray Re-entry Device (Boston Scien-
tific, Natick, MA).2,7,20,30 These devices use a curved
needle to puncture through the intima for reentry into
the distal true lumen. This significantly increases the
chance of successful reentry and thus the success rate
of this crossing method.30
User
In the User approach, all the control of the crossing
path is given to the user. In this approach, the user of
the crossing device is able to actively steer through the
CTO, called Directly Steered Crossing. If the user so
desires, heavily calcified regions can be circumnavi-
gated. Furthermore, the addition of a tip sensor in
Sensor Enhanced Crossing can give additional visual
information about the position of the crossing device
in relation to the direct environment. This information
can, subsequently, be used as an extra navigational aid.
Directly Steered Crossing
Cable Actuation (in Use for Peripheral and Coronary
CTOs) Currently, a number of cable-actuated
guidewires (£0.4 mm) are available that can be actively
steered through CTOs. The latest Cordis guidewires
Shinobi and Wizdom enable tip deflection in one or two
directions with a minimum bending angle of 45 degrees.63
Furthermore, the Venture Catheter (St. Jude Medical,
MN) is a support catheter able to deflect all commercially
available 0.36 mm guidewires with angles up to 90.63
Electroactive Polymer Actuation (Proposed for Acute
Occlusions) Couvillon10 describes a directly steerable
crossing device that uses multiple electroactive polymer
actuators to steer the tip of the crossing device (see
Fig. 7). These electroactive polymers act as joints,
which enable direct steerability of the crossing device.
By increasing the number of electroactive polymers,
complex shapes such as three-dimensional s-curves can
be achieved.
Segmented Balloons (Proposed for Peripheral CTOs,
Coronary CTOs, and Acute Occlusions) The device
proposed by Petrucci41 uses a segmented intravascular
balloon to steer the crossing device in plane (see
Fig. 7). In plane steering can assure a central position
with respect to the CTO, but does not allow for
adjusting the tip orientation. A major advantage of
this steering technique is, however, that by keeping
contact with the blood vessel wall, the buckling
resistance is increased.
Directional Stiffness (Proposed for Peripheral and
Coronary CTOs) Melsheimer et al.35 propose a
guidewire with a specialized tip geometry for steering
(see Fig. 7). In this approach, the difference in friction
(between the tip and occlusion) caused by the
orientation of the guidewire in the occlusion is used
for steering. By rotating the guidewire, the tip
orientation is changed and in this way the direction
of motion. A similar approach is suggested by
Eckhouse et al.13
FIGURE 7. User: directly steered crossing. Color indica-
tions: Red 5 blood vessel wall. Yellow 5 plaque material.
Light blue 5 balloon. Bright Pink 5 electroactive actuators.
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External Magnetic/Electric Field (in Use for Peripheral
and Coronary CTOs) Magnetically or electrically
enabled crossing tools have coils, magnets, or
ferromagnetic materials incorporated inside their tip
to enable tip deflection by an external electric or
magnetic field outside the patient’s body (see Fig. 7
for a schematic representation of such systems). A
currently available fully integrated magnetic navigation
system for guidewires and catheters is the Niobe MNS
(Stereotaxis, St. Louis, MO) with the associated FDA-
approved magnetic PowerAssert Radiofrequency
Guidewire.63 Examples of other magnetically enabled
guidewires are Titan (Stereotaxis, St. Louis, MO) and
Pegasus (Stereotaxis, St. Louis, MO).7
Sensor Enhanced Crossing
The determination of the precise 3D position and
orientation of the CTO and crossing device is often
difficult to determine with conventional Computed
Tomography (CT) images. This uncertainty about 3D
tip position of the crossing device can lead to blood
vessel wall trauma, false lumen creation, and even
discontinuation of the procedure. Therefore, there is a
need for (intravascular) imaging methods that can give
the user additional information about the orientation,
position, and tissue types in front of the crossing de-
vice.
The latest advance in external cardiac imaging is
Multislice Computed Tomography (MSCT). The main
fundamental advantage of MSCT in comparison to
conventional CT is the ability to visualize the CTO in
3D. AlthoughMSCT is currently mainly used as a pre-
operative imaging technique, the new generation 128-
slice MSCT scanners are finding their way into the
intervention room for real-time 3D imaging of the
coronaries.58 Unfortunately, the resolution level is still
relatively low and does not allow for reconstruction of
thin intraluminal channels or thin collaterals.51 Fur-
thermore, one of the major concerns in usingMSCT is
the radiation dose received by the patient.51
The latest advances in non-iodizing intravascular
cardiac imaging techniques (with a higher resolution
than MSCT) are Optical Coherence Tomography
(OCT) and IntraVascular UltraSound (IVUS) (see
Fig. 8 for a schematic representation of both systems).
In OCT, different tissue types are identified based on
unique patterns of absorption, reflection, and scatter of
near-infrared light.27 In IVUS, the difference in re-
flectance of ultrasonic sound waves is used to distin-
guish different tissue types.62
OCT (or Optical Coherence Reflectometry (OCR))
is currently applied as a tissue-selective (imaging) sys-
tem in two FDA-approved micro-catheters: the Safe-
Cross Radiofrequency Total Occlusion Crossing (TOC)
Guidewire System (Ø0.36 mm, Intraluminal Thera-
peutics, Carlsbad, CA; in use for coronary CTOs)27,50,55
and theOcelot catheter (Avinger, Redwood City, CA; in
use for peripheral CTOs).49 In the TOC, the OCR
information is displayed as a waveform and a visible
and audible signal warns the interventionist when the
device tip approaches the blood vessel wall. A currently
available IVUS catheter is the Eagle Eye IVUS Catheter
(Volcano, San Diego, CA; in use peripheral and coro-
nary CTOs).51 Furthermore, Webster62 describes a de-
vice that uses IVUS for clot identification in
combination with a laser for crossing (see Fig. 8).
Two other imaging techniques for intravascular
imaging are proposed in the patented literature using a
laser32 and electrical impedance.28 In the laser
approach, tissue distinction is accomplished by com-
paring the optical fluorescent characteristics of the
excited tissue to that of known healthy and plaque
tissue (see Fig. 8 for a schematic representation of this
system).32 In the electrical impedance approach, La-
fontaine et al.28 suggest using the difference in electri-
cal impedance between the plaque and the blood vessel
wall to distinguish between these two tissue types (see
Fig. 8).
DISCUSSION
Devices in Clinical Practice
Many of the identified devices are specifically de-
signed for crossing total occlusions. Of the discussed
FIGURE 8. User: sensor enhanced crossing. Color indica-
tions: Red 5 blood vessel wall. Yellow 5 plaque material.
Pink 5 ultrasound transducer. Light blue 5 balloon.
Orange 5 optical coherence tomography imaging. Pur-
ple 5 laser. Bright Green 5 fluorescence. OCT, optical
coherence tomography; IVUS, intravascular ultrasound.
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devices, however, only a handful is FDA-approved and
actually used in clinical practice. Even though quite
promising results are achieved with the FDA-approved
crossing devices, there is still improvement needed to
increase the success rates in the highly calcified CTOs.
Abandoned Crossing Devices
Even though many different devices have been
developed for the treatment of heavily calcified CTOs,
most of these devices never progressed beyond the
investigational phase because of two main reasons.
Firstly, many devices demonstrated excessively high
rates of complications, particularly dissection or per-
foration.55 Secondly, the success rates of many of
abandoned devices was not significantly higher than
those achieved by standard crossing devices.55 Exam-
ples of failed CTO devices are axially rotating drill
devices and several (excimer) lasers.55
Abandoned device designs can give important clues
to the reasons for the excessive complication rate. First
of all, the above-mentioned devices all exhibit an ex-
tremely limited ability to adjust to the 3D shape of the
blood vessel and CTO. This makes these instruments
potentially more prone to cause trauma, especially in
tortuous CTOs. Secondly, lasers (and fluid jets) give
limited feedback about the axial depth of the beam,
making these devices more difficult to control. Thirdly,
many of the axially rotating drill devices are designed
with sharp edges to increase the chance of a successful
crossing action, which at the same time increases the
chance of blood vessel wall trauma.
Aside from directly visible damage to the blood
vessel wall, other adverse events such as heat damage
can also seriously impair the blood vessel wall and lead
to serious complications. Lasers have been known to
cause thermal damage to the surrounding tissues,
warranting the slow advancement of 1 mm/s to in-
crease absorption within the plaque.63 Furthermore,
we assume that the proposed device relying on spark
erosion6 and high speed rotating drills5,12,23,37,42 can
cause heat damage to the blood vessel wall as well,
which may have also have been a potential factor that
led to abandonment.
It could be argued that if the benefits outweigh the
risks, the device could still be used in clinical practice.
Preventive measures could then be taken to minimize
the risks of blood vessel wall damage. However, in
most cases the devices were not only associated with an
increased risk of blood vessel wall damage, but were
also not very beneficial when it comes to increasing the
success rate of the intervention in comparison to
standard crossing devices.55 Success rates with lasers in
coronary CTOs, for example, did not exceed 61%.63
Current Crossing Devices
In recent years, promising results have been illus-
trated using crossing devices such as the Frontrunner
XP and the Crosser catheter. Success rates as high as
90% are reported with these new crossing devices. This
raises the question if there is still a need for innovative
crossing devices. The answer to this question is yes.
The reported high success rates with the new
crossing devices are sometimes deceptive. The highest
success rates are reported in peripheral CTOs or
occlusions younger than 3 months old, and are often in
the hands of very experienced operators. For example,
the high success rate achieved with Frontrunner XP and
Enabler-P of 91 and 86.4%, respectively, were both
achieved in peripheral vessels.63 Peripheral and
younger CTOs are usually less calcified than coronary
CTOs and thus easier to cross.19,55 This is substanti-
ated by the fact that even though Frontrunner XP was
originally designed for crossing coronary CTOs, more
recently, the device has been increasingly used to
facilitate guidewire crossing in peripheral CTOs.9
Furthermore, it was found that he extent of calcifica-
tion increases the frequency of complications and de-
creases the success rate of Frontrunner XP.9
Crossing heavily calcified lesions is, therefore, still
the limiting factor for success in most devices. Next to
Frontrunner XP, the age of the CTO, calcification, and
the length of the occlusion, were indicated to nega-
tively affect the success rate in ATD, Wildcat catheter,
Safe-Cross, and the vibrational angioplasty device
(Medical Miracles, UK).12,27,42,63 Calcium is more
resistant to compression and resection, and thus
requires higher energy input for crossing. Therefore, to
improve the success rate the energy delivery on the
CTO needs to increase.
Limited directional control is also an issue in most
of current crossing device designs. For example, the
vibrational angioplasty device is considered unsuit-
able for smaller and tortuous vessels due to limited
directional control.63 Additionally, Crosser Catheter
has the tendency to move straight inside a vessel, which
limits its trackability and increases the chance of
entering side-branches and dissection.63 As coronary
CTOs tend to be smaller in diameter and more tortu-
ous than peripheral CTOs, they pose a bigger chal-
lenge. Adding the ability to actively navigate through
occlusions, such as in steerable guidewires, only solves
part of this problem, as visual information is still
needed about the relative position of the device in
relation to the CTO.
The position of the CTO (in the coronary or
peripheral vasculature) is also of influence on the type
of crossing device that can be applied in a safe manner.
The heart is sensitive to arrhythmogenic effects caused
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by cavitation, vibration, and heat (for example).
Therefore, the use of lasers, mechanical vibration, and
cavitation for crossing coronary CTOs are relatively
high risk. Since the chance of arrhythmogenic effects is
minimal in crossing peripheral CTOs, the treatment
options, and the use of a laser (for example), is less
risky.
Proposed Crossing Devices
Next to the previously discussed devices, many de-
vices are proposed for crossing CTOs (amongst other
occlusion types), but not (yet) seen in clinical practice
or trials. Unfortunately, no information is found about
the reason that these are not (yet) clinically available.
Therefore, assumptions are made based on design
considerations.
In general, the medical environment, including the
size, shape, and biomechanical properties of the blood
vessel and CTO, in which the device needs to function,
should be the starting point of the design process. Lack
of proper research into the medical environment can
lead to device malfunction or procedural failure, which
are both assumed to have occurred in several of the
proposed designs.
Size restrictions of the device, based on the position
of the CTO, will give important clues if certain work-
ing principles are feasible or if new issues, such as
insufficient force generation, can arise. Additionally,
the limitations and abilities of different manufacturing
techniques should also be taken into account. Some of
the described devices, such as the drive belt mechanism
proposed by Thompson et al.,57 are most likely
impossible to manufacture at the 1 mm diameter scale
needed for the coronary application.
The biomechanical properties of the CTO and the
blood vessel wall are also important factors to take
into account. Since the inability to successfully cross
the CTO is the most common failure mode, mainly due
to buckling of the guidewire, the buckling resistance of
the device should be a major factor to take into
account in the design. However, high buckling resis-
tance should not go hand in hand with an increased
risk of blood vessel wall damage, as is the case in lasers
and fluid jets. Since buckling and blood vessel wall
trauma can both lead to procedural failure, it is
important to find middle ground, which is seen in the
centerline crossing devices.
Next to individual properties, the difference in
biomechanical properties within the CTO itself, as well
as the biomechanical difference of the CTO and blood
vessel should be taken into account when designing.
For example, in the crack propagation crossing
method, proposed by Zakai et al.,64 it is assumed that
the CTO will crack before the blood vessel wall is
damaged. However, it is more likely that the pressure
needed to cross a heavily calcified CTO is higher than
the pressure needed to damage, unnaturally stretch, or
even rupture, the blood vessel wall. Additionally, it is
assumed that precise steering with the directional
stiffness guidewire is difficult since the friction between
the different tissue types inside the CTO will differ,
resulting in varying deflections of the tip.35
Finally, non-design related factors that could have
halted development of the proposed devices are the
required high-risk and high-cost investments to devel-
op, test, legalize, and manufacture a clinical tool. Some
of the proposed devices have probably never made it to
a testing phase. Which devices this involves is unclear.
Future Crossing Device
Desired Crossing Path
The question remains that if a crossing device was to
be developed that is technically able to cross the
occlusion, what would then be the best crossing path.
All the described crossing paths and associated cross-
ing devices have their advantages and disadvantages.
However, the two most important factor that needs to
be taken into account when determining the best
crossing path is the chance of blood vessel wall dam-
age and buckling resistance of the crossing tool;
allowing for crossing heavily calcified regions.
In order to prevent blood vessel wall trauma, it is
important to be able to steer clear of the blood vessel
wall. Therefore, the crossing device should be able to
adapt to the direction and shape of the blood vessel.
Since in the Device approach (A), the environment and
user are of minimal influence on the crossing path, this
crossing method is not considered feasible for inte-
gration in a future crossing device. However, pre-
venting blood vessel wall contact and damage can be
achieved in the Environment (B) and User (C) defined
crossing.
The most obvious choice seems to be to give the user
full control of the crossing action (User approach).
However, the image capability, especially in 3D, of the
conventional C-arcs in most clinics, is still limited for a
real-time application. Therefore, it is questionable
whether the interventionist would have sufficient
information at hand to prevent blood vessel wall
trauma.
Safe intraluminal crossing can be assured by giving
the interventionist additional information with a tis-
sue-selective imaging technique (Sensor Enhanced
Crossing) or by adding a mechanism that ensures the
device follows the path of least resistance or centerline
through the CTO. Even though both approaches can
assure safe crossing, another important factor that
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should be taken into account is the buckling resistance
of the crossing device. In this respect, the Centerline
Crossing approach is most promising, due to the in-
crease of effective cross-sectional diameter.
Therefore, in order to ensure both safe and suc-
cessful crossing of the most heavily calcified CTOs, it
not only important to steer clear of the blood vessel
wall, but also to prevent buckling. This can be assured
by combining the user approach, in which the inter-
ventionist is able to actively navigate through the CTO
and is thus able to circumnavigate heavily calcified
regions, with the environment approach, where the
blood vessel wall or path of least resistance is followed
through the CTO. Furthermore, by adding a tissue-
selective imaging technique, as in Sensor Enhanced
Crossing, the success rate might be improved by giving
the user additional information about the consistency
and shape of the CTO.
Desired Functionality
According to the experts, if a new device for CTO
crossing were to be developed it would be necessary to
incorporate three functions: (1) crossing of the harder
calcified regions, (2) visualization, and (3) steerability.
Some crossing devices were identified that have
incorporated one of these functions, such as visual-
ization in the Ocelot Catheter (Avinger, Redwood City,
CA).49 However, not a single device exists that inte-
grates all three functionalities.
In order to achieve all three described functions in a
future device it is necessary to look into the possibility
of further miniaturization of the device components or
to look into shared component use. In the latter
approach components are used to achieve multiple
functions, such as steering and crossing of heavily
calcified regions. An example of a multifunctional de-
vice component is a miniature cable. Cables can be used
for steering as in the steerable guidewires, visualization
as in OCT and IVUS, actuators as in rotating drills and
drive belt mechanisms, and for crossing as in lasers.
Cables are thus very versatile, and are available in many
different shapes, sizes, and materials. However, minia-
ture cables lack buckling resistance at the required small
sizes. It would, therefore, be necessary to look into
additional measures to ensure sufficient buckling resis-
tance, such as balloons or expandable structures.
It may also be possible to design a highly effective
and safe crossing device without incorporating all three
functionalities described by the experts. By focusing on
increasing the buckling resistance and preventing
blood vessel wall damage, other options, such as an
inherent safe device that is able to cross the harder
calcified regions and follows the blood vessel wall, may
be explored.
CONCLUSION
In this review, a comprehensive overview is given of
current, proposed, and abandoned devices for crossing
total occlusions, including CTOs. The identified
crossing devices were subdivided based on their
crossing paths through the occlusion and subsequently
reviewed based on their ability to safely cross heavily
calcified CTOs. Insight is given into reasons for
abandonment of past crossing devices, needed
improvement to current crossing devices, and design
considerations for future crossing devices. To improve
the success rate for PCI in CTOs in future it is argued
that a future crossing device should be able to safely
and efficiently cross the hardest CTO lesions using a
combined user approach, in which the interventionist is
able to actively navigate the crossing device, and en-
vironment approach, to allow for an inherent safe de-
vice with improved buckling resistance.
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